mGluR1 Negative Allosteric Modulators: An Alternative Metabotropic Approach for the Treatment of Schizophrenia

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/978-3-0346-0241-9_7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

  2009cited by this paper
• Correlation of receptor occupancy of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse brain with in vivo activity of allosteric mGluR1 antagonists.

  2009cited by this paper
• Unique Antipsychotic Activities of the Selective Metabotropic Glutamate Receptor 1 Allosteric Antagonist 2-Cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one

  2009cited by this paper
• Face-washing behavior induced by the group I metabotropic glutamate receptor agonist (S)-3,5-DHPG in mice is mediated by mGlu1 receptor.

  2008cited by this paper
• Presynaptic mGlu1 and mGlu5 autoreceptors facilitate glutamate exocytosis from mouse cortical nerve endings.

  2008cited by this paper
• Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.

  2008cited by this paper
• Pharmacological Effects of the Metabotropic Glutamate Receptor 1 Antagonist Compared with Those of the Metabotropic Glutamate Receptor 5 Antagonist and Metabotropic Glutamate Receptor 2/3 Agonist in Rodents: Detailed Investigations with a Selective Allosteric Metabotropic Glutamate Receptor 1 Antago

  2008cited by this paper
• Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

  2007cited by this paper
• Characteristics of object location memory in mice: Behavioral and pharmacological studies.

  2007cited by this paper
• Pharmacological Characterization of a New, Orally Active and Potent Allosteric Metabotropic Glutamate Receptor 1 Antagonist, 4-[1-(2-Fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC)

  2007cited by this paper
• Stimulation of group I mGlu receptors in the ventrotegmental area enhances extracellular dopamine in the rat medial prefrontal cortex

  2006cited by this paper
• Regulation of Extracellular Glutamate in the Prefrontal Cortex: Focus on the Cystine Glutamate Exchanger and Group I Metabotropic Glutamate Receptors

  2005cited by this paper
• mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition.

  2005cited by this paper
• Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task.

  2005cited by this paper
• Glutamate as a therapeutic target in psychiatric disorders

  2004cited by this paper
• Metabotropic glutamate 1 receptor distribution and occupancy in the rat brain: a quantitative autoradiographic study using [3H]R214127.

  2004cited by this paper
• Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs

  2004cited by this paper
• Selective action of (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell.

  2004cited by this paper
• JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist.

  2004influential reference
• Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders

  2003influential reference
• Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in Rodents

  2003cited by this paper
• Disruption of prepulse inhibition in mice lacking mGluR1

  2003cited by this paper
• Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans

  2003cited by this paper
• N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity

  2003cited by this paper
• Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats.

  2002cited by this paper
• Glutamate Receptors and Nociception

  2001cited by this paper
• Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620.

  2001cited by this paper
• Molecular determinants of metabotropic glutamate receptor signaling.

  2001cited by this paper
• Schizophrenia: the fundamental questions

  2000cited by this paper
• The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing.

  2000cited by this paper
• Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor.

  2000cited by this paper
• LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine.

  2000cited by this paper
• Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models.

  1999cited by this paper
• Intracerebral administration of metabotropic glutamate receptor agonists disrupts prepulse inhibition of acoustic startle in Sprague-Dawley rats

  1999cited by this paper
• The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.

  1999cited by this paper
• Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

  1998influential reference
• Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications.

  1997cited by this paper
• Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex

  1997cited by this paper
• Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia

  1995cited by this paper
• Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity.

  1994cited by this paper
• Reduced hippocampal long-term potentiation and context-specific deficit in associative learning in mGluR1 mutant mice.

  1994cited by this paper
• Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice.

  1994cited by this paper
• Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate.

  1993cited by this paper
• Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: An in situ hybridization study in adult and developing rat

  1992cited by this paper
• Gating and habituation of the startle reflex in schizophrenic patients.

  1992cited by this paper
• Recent advances in the phencyclidine model of schizophrenia.

  1991cited by this paper
• Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

  1988cited by this paper
• Psychopharmacology : a generation of progress

  1978cited by this paper

• Targeting metabotropic glutamate receptors for novel treatments of schizophrenia

  2017cites this paper